Ocular Therapeutix Inc (OCUL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ocular Therapeutix Inc (OCUL) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-65.99 Million) by net assets ($581.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ocular Therapeutix Inc (OCUL) liquidity interval to measure how many days the company can operate on defensive assets alone.
Ocular Therapeutix Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ocular Therapeutix Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Ocular Therapeutix Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ocular Therapeutix Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fidelis Insurance Holdings Limited
NYSE:FIHL
|
0.102x |
|
Shenzhen Changhong Tech
SHE:300151
|
0.045x |
|
Vimian Group AB
ST:VIMIAN
|
0.080x |
|
HUTCHMED (China) Limited
F:H7T1
|
-0.071x |
|
WindSun Science & Technology Co. Ltd. A
SHG:688663
|
N/A |
|
China Tianying Inc
SHE:000035
|
0.013x |
|
Lovisa Holdings Ltd
AU:LOV
|
1.157x |
|
Luoyang Xinqianglian Slewing Bearin
SHE:300850
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Ocular Therapeutix Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ocular Therapeutix Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see OCUL stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $654.31 Million | $-204.88 Million | -0.313x | +26.68% |
| 2024-12-31 | $315.34 Million | $-134.68 Million | -0.427x | +44.58% |
| 2023-12-31 | $91.13 Million | $-70.23 Million | -0.771x | +54.25% |
| 2022-12-31 | $35.38 Million | $-59.60 Million | -1.685x | -126.17% |
| 2021-12-31 | $88.00 Million | $-65.55 Million | -0.745x | -5.84% |
| 2020-12-31 | $76.09 Million | $-53.55 Million | -0.704x | -103.29% |
| 2019-12-31 | $-3.63 Million | $-77.58 Million | 21.371x | +1657.47% |
| 2018-12-31 | $35.88 Million | $-49.23 Million | -1.372x | +28.92% |
| 2017-12-31 | $26.15 Million | $-50.47 Million | -1.930x | -195.27% |
| 2016-12-31 | $52.01 Million | $-34.00 Million | -0.654x | -73.58% |
| 2015-12-31 | $89.59 Million | $-33.74 Million | -0.377x | -7.86% |
| 2014-12-31 | $58.70 Million | $-20.50 Million | -0.349x | -264.23% |
| 2013-12-31 | $-59.47 Million | $-12.64 Million | 0.213x | -21.25% |
| 2012-12-31 | $-46.61 Million | $-12.59 Million | 0.270x | -- |
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more